DiscoverResearch To Practice | Oncology VideosMetastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Update: 2025-11-29
Share

Description

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: 

  • Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00 )
  • SERD Monotherapy (13:34 )
  • SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58 )
  • SERDs for "Molecular Progression" — The SERENA-6 Study (41:25 )

CME information and select publications

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Dr. Neil Love